Telomerase as an anti-cancer drug target: Will it fulfil its early promise?

Anti-Cancer Drug Design

Volumn 14, Issue 4, 1999, Pages 349-354

  Newbold, Robert F ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Anti cancer drugs; Targeting; Telomerase

Indexed keywords

ANTINEOPLASTIC AGENT; RIBONUCLEOPROTEIN; TELOMERASE;

BIOCHEMISTRY; CANCER CELL; CELL IMMORTALIZATION; CELL SURVIVAL; DRUG DESIGN; DRUG TARGETING; DYNAMICS; ENZYME INACTIVATION; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TELOMERE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL AGING; ENZYME INHIBITORS; HUMANS; MICE; MICE, KNOCKOUT; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032747964     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91, 25.
2. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science, 279, 349.
3. Broccoli D., Young J.W., Delange T. (1995) Telomerase activity in normal and malignant hematopoietic-cells. Proceedings of the National Academy of Sciences, USA, 92, 9082.
4. Bryan T.M., Englezou A., DallaPozza L., Dunham M.A., Reddel R.R. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medicine, 11, 1271.
5. Bryan T.M., Englezou A., Gupta J., Bacchetti S., Reddel R.R. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO Journal, 14, 4240.
6. Carman T.A., Afshar C.A., Barrett J.C. (1998) Cellular senescence in telomerase-expressing Syrian hamster embryo cells. Experimental Cell Research, 244, 33.
7. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., DePinho R.A. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 97, 527.
8. Cuthbert A.P., Bond J., Trott D.A., Gill S., Parkinson E.K., Marriott A., Cooper C.S., Newbold R.F. (1999) Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. Journal of the National Cancer Institute, 91, 37.
9. Feng J.L., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J.H., Le S.Y., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. (1995) The RNA component of human telomerase. Science, 269, 1236.
10. Greaves M. (1996) Is telomerase in cancer due to selection of stem cells and differentiation arrest. Trends in Genetics, 12, 127.
11. Greenberg R.A., Allsopp R.C., Chin L., Morin G.B., DePinho R.A. (1998) Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene, 16, 1723.
12. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G. J., Singer R.H., Greider C.W., DePinho R.A. (1999) Short dysfunctional telomeres impair tumorigenesis in the INK4a (Delta 2/3) cancer-prone mouse. Cell, 97, 515.
13. Harle-Bachor C., Boukamp P. (1996) Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proceedings of the National Academy of Sciences, USA, 93, 6476.
14. Harley C.B. (1991) Telomere loss - mitotic clock or genetic time bomb. Mutation Research, 256, 271.
15. Hayflick L., Moorhead P.S. (1961) The serial cultivation of human diploid cell strains. Experimental Cell Research, 25, 585.
16. Herrera E., Samper E., Blasco M.A. (1999a) Telomere shortening in mTR(-/-) embryos is associated with failure to close the neural tube. EMBO Journal, 18, 1172.
17. Herrera E., Samper E., Martin-Caballero J., Flores J.M., Lee H.W, Blasco M.A. (1999b) Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO Journal, 18, 2950.
18. Horikawa I., Oshimura M., Barrett J.C. (1998) Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Molecular Carcinogenesis, 22, 65.
19. Ishikawa F. (1997) Telomere crisis, the driving force in cancer cell evolution. Biochemical and Biophysical Research Communications, 230, 1.
20. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G. M., Wright W.E., Weinrich S.L., Shay J.W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011.
21. Le S., Moore J.K., Haber J.E., Greider C.W. (1999) RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics, 152, 143.
22. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q.Y., Bacchetti S., Haber D.A., Weinberg R.A. (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90, 785.
23. Newbold R.F. (1997) Genetic control of telomerase and replicative senescence in human and rodent cells. Ciba Foundation Symposium, 211, 177.
24. Newbold R.F., Overell R.W. (1983) Fibroblast immortality is a prerequisite for transformation by EJ C-Ha-ras oncogene. Nature, 304, 648.
25. Newbold R.F., Overell R.W., Connell J. (1982) Induction of immortality is an early event in the malignant transformation of mammalian cells by carcinogens. Nature, 299, 633.
26. Newbold R.F., Cuthbert A.P., Themis M., Trott D.A., Blair A.L., Li W. (1993) Cell immortalization as a key, rate-limiting event in malignant transformation: approaches toward a molecular genetic analysis. Toxicology Letters, 67, 211.
27. Olovnikov A.M. (1973) A theory of marginotomy: the incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. Journal of Theoretical Biology, 41, 181.
28. Rudolph K.L., Chang S., Lee H.W, Blasco M., Gottlieb G.J., Greider C., DePinho R.A. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96, 701.
29. Russo I., Silver A.J.R., Cuthbert A.P., Newbold R.F. (1998) A telomere-independent senescence mechanism is the sole barrier to immortalization in rodent cells. Oncogene 17, 3417.
30. Shay J.W., Wright W.E. (1996) The reactivation of telomerase activity in cancer progression. Trends in Genetics, 12, 129.
31. Suzui N., Yoshimi N., Kawabata K., Mori H. (1999) The telomerase activities in several organs and strains of rats with ageing. Laboratory Animals, 33, 149.
32. Tahara H., Yasui W., Tahara E., Fujimoto J., Ito K., Tamai K., Nakayama J., Ishikawa F., Ide T. (1999) Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene, 18, 1561.
33. Tanaka H., Shimizu M., Horikawa I., Kugoh H., Yokota J., Barrett J.C., Oshimura M. (1998) Evidence for a putative telomerase repressor gene in the 3p14.2-p21.1 region. Genes Chromosomes and Cancer, 23, 123.
34. Wright W.E., Brasiskyte D., Piatyszek M.A., Shay J.W. (1996) Experimental elongation of telomeres extends the lifespan of immortal×normal cell hybrids. EMBO Journal, 15, 1734.
35. Wynford-Thomas D., Jones C.J., Wyllie F.S. (1996) The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression. Biological Signals, 5, 139.